LAUSR

BackgroundThe efficacy of daprodustat for the treatment of anemic patients with chronic kidney disease (CKD) remains controversial. The aim of the study is to perform a meta-analysis of randomized controlled trials to evaluate the efficacy and safety of daprodustat for anemic patients with chronic kidney disease.MethodsWe searched Medline, Embase, Science Citation Index, Cochrane Central Register of Controlled Trials, and Clinical Trial Registries for randomized controlled trials comparing daprodustat with placebo for anemic patients with CKD.ResultsFour studies were included. Compared with placebo groups, daprodustat groups significantly increased hemoglobin (WMD 1.29 g/dL; 95% CI 0.96–1.62, p < 0.00001), transferrin (WMD 0.67 g/dL; 95% CI 0.45–0.89, p < 0.00001), and total iron binding capacity (WMD 9.97 g/dL; 95% CI 6.07–13.8, p < 0.00001). Daprodustat groups significantly decreased hepcidin (WMD − 76.1 μg/L; 95% CI − 91.8 to − 60.3, p < 0.00001) and ferritin (WMD − 63.6 μg/L; 95% CI − 96.6 to − 30.7, p = 0.0002) compared with that of placebo groups. In addition, there was no significant difference in adverse events between the two groups.ConclusionDaprodustat could improve hemoglobin without increasing adverse events in the short term. Daprodustat may be another valuable choice for anemic patients with chronic kidney disease in the future.